Floatz Rating
B61/100
Confidence
Indicative
Sponsor
The University of Hong Kong
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03485417CT.gov Substance Misuse To Psychosis for Stimulants | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Substance Abuse
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Paliperidone (this asset) | The University of Hong Kong | P2/3 | B · 61 |
| Quetiapine | Boston Medical Center | P4 | BBB |
| Risperidone | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | University of Texas Southwestern Medical Center | P4 | BB |
| Brexpiprazole | University of Massachusetts, Worcester | P4 | BB |
| Olanzapine | Augusta University | P4 | BB |
| Clozapine | Augusta University | P4 | BB |
| Valproic Acid | Creighton University | P4 | BB |
| Oxycodone | Member Companies of the Opioid PMR Consortium | P4 | BB |
+18 more in the Substance Abuse cohort
Other indications for Paliperidone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P4 | BBB · 78 |
| Psychotic Disorder | — | P4 | BBB · 76 |
| Schizophrenia | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Paliperidone in Substance Abuse. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/paliperidone-substance-abuse
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →